[Ip-health] Joint NGO Statement: LDC Pharma Exemption
sangeeta at twnetwork.org
Fri Nov 6 08:14:00 PST 2015
The LDC pharmaceutical exemption is from Sections 5 and 7 of the TRIPS
Agreement. This is what was granted in para 7 of the Doha Declaration. The
same thing has been granted today by the TRIPs Council only for an
additional 17 years.
Section 5 is on patents and Section 7 is on protection of undisclosed
So the reference in the NGO statement to test data is in connection with
protection of undisclosed information under Section 7 of TRIPS Agreement.
Hope this clarifies.
From: Francisco <francisco_rossi at hotmail.com>
Date: Fri, 6 Nov 2015 15:02:18 +0000
To: Sangeeta Shashikant <sangeeta at twnetwork.org>,
"ip-health at lists.keionline.org" <ip-health at lists.keionline.org>
Subject: RE: [Ip-health] Joint NGO Statement: LDC Pharma Exemption
Just for clarification, this is the first time we heard about an obligation
to protect test data for least developed countries, additionally to patents.
As far as we understand, data exclusivity is a TRIPS Plus measure not
contemplated before in the discussions of transition period to protect
pharmaceutical products with patents in LDCs. Is this a new goal by Pharma?
is this a "compromise" solution? Do you have aditional information on that?
Thanks from Colombia where we are completing 13 years of painful data
> Date: Fri, 6 Nov 2015 13:29:49 +0000
> From: sangeeta at twnetwork.org
> To: ip-health at lists.keionline.org
> Subject: [Ip-health] Joint NGO Statement: LDC Pharma Exemption
> JOINT NGO STATEMENT
> TRIPS Council Decision On Extension of the Transition Period Concerning
> Pharmaceutical Products
> Today (6th November), the WTO-TRIPS Council adopted a decision granting
> Least Developed Countries (LDCs) an exemption from patents and test data
> protection for pharmaceutical products for a duration of 17 years.
> With this exemption, LDCs will not be obliged to implement or apply or to
> enforce patents as well as test data protection for pharmaceutical
> products until 1 January 2033.
> This decision is without prejudice to the right of LDCs to seek additional
> extensions of transition periods pursuant to Article 66.1 of the TRIPS
> Agreement. This is consistent with LDCs¹ right to not implement the TRIPS
> Agreement at this level of their development.
> The TRIPS Council also adopted a recommendation to the WTO General Council
> for waivers from mailbox and exclusive marketing rights until 1 January
> 2033. Hence, LDCs will not be obliged to make available a mechanism for
> filing patent applications for pharmaceutical products (mailbox) or to
> grant exclusive marketing rights to such applications until 1 January
> In numerous letters on this matter, civil society organizations have
> highlighted the critical importance of this exemption from pharmaceutical
> patents and test data protection for the world¹s poorest nations that
> suffer massive challenges in facilitating access to affordable treatment
> for infectious as well as non-communicable diseases. Considering the dire
> socio-economic conditions in these countries, they also need maximum
> flexibility in implementation of national laws to improve their
> technological base and to boost local production of affordable medicines.
> For this reason, the LDCs¹ request for a pharmaceutical transition period
> until a country ceases to be an LDC, has received almost universal
> unequivocal support from civil society globally, international and UN
> agencies (WHO, UNDP, UNAIDS, UNITAID) and the European Union with no
> declared opposition from the WTO members except for the United States.
> Had the WTO-TRIPS Council granted the LDCs their desired and valid
> requests, it would have demonstrated to the world that the WTO will take
> the necessary steps to protect the poor and vulnerable. Instead,
> unfortunately due to strong opposition mainly from the US, the WTO-TRIPS
> Council reached a decision to accord LDCs¹ a transition period of 17
> Nevertheless, with this decision we urgently call on all Least Developed
> Countries to actively use the created policy space this renewed transition
> period provides and accordingly to take immediate steps to amend their
> respective national laws to exclude pharmaceutical products from patent
> protection and test data protection with explicit provisions that this
> would be until 1 January 2033 or the expiry of such later transition
> period that may be granted by the WTO Council for TRIPS.
> The Asia Pacific Network of People living with HIV/AIDS (APN+)
> Both ENDS (Netherlands)
> Bern Declaration (Switzerland)
> EquityBD (Bangladesh)
> Coastal Association for Societal Transformation Trust (Bangladesh)
> Center for Health Human Rights and Development (CEHURD)(Uganda)
> Health Action International (HAI)
> Health GAP (Global Access Project)
> Knowledge Ecology International
> LDC Watch
> MSF Access Campaign
> Public Citizen
> Third World Network
> Yolse (Burkina Faso)
> Ip-health mailing list
> Ip-health at lists.keionline.org
More information about the Ip-health